Xvivo Perfusion AB (XVIPF) Stock Statistics & Valuation Metrics

Xvivo Perfusion AB has a market cap or net worth of $651.37M. The enterprise value is $6.74B.

Market Cap

$651.37M

Enterprise Value

$6.74B

Xvivo Perfusion AB has 31,499,470 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

31,499,470

Owned by Insiders

―

Owned by Institutions

8.06%

Xvivo Perfusion AB’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 2.68%.

Return on Equity (ROE)

0.01

Return on Assets (ROA)

0.01

Return on Invested Capital (ROIC)

2.68%

Return on Capital Employed (ROCE)

0.04

Revenue Per Employee

3.92M

Profits Per Employee

121.56K

Employee Count

207

Asset Turnover

0.34

Inventory Turnover

1.12

The current PE Ratio of Xvivo Perfusion AB is 49.88. Xvivo Perfusion AB’s PEG ratio is 0.15.

PE Ratio

49.88

PS Ratio

6.70

PB Ratio

2.84

Price to FCF

33.54

Price to Operating Cash Flow

23.91

PEG Ratio

0.15

In the last 12 months, Xvivo Perfusion AB had revenue of 812.16M and earned 25.16M in profits. Earnings per share was 0.80.

Revenue

812.16M

Gross Profit

533.50M

Operating Income

93.02M

Pretax Income

38.56M

Net Income

25.16M

EBITDA

153.14M

Earnings Per Share (EPS)

0.80

In the last 12 months, operating cash flow was 268.77M and capital expenditures -164.14M, giving a free cash flow of 191.56M billion.

Operating Cash Flow

268.77M

Free Cash Flow

191.56M

Free Cash Flow per Share

6.08

Xvivo Perfusion AB pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

2.98%

Earnings Yield

2.00%

Beta

1.20

52-Week Price Change

18.02%

50-Day Moving Average

23.38

200-Day Moving Average

25.80

Relative Strength Index (RSI)

41.36

Average Volume (3m)

622

Xvivo Perfusion AB upcoming earnings date is Jan 28, 2027, Before Open (Not Confirmed).

Last Earnings Date

Oct 22, 2026

Next Earnings Date

Jan 28, 2027

Ex-Dividend Date

―

Xvivo Perfusion AB as a current ratio of 5.77, with Debt / Equity ratio of 5.90%

Current Ratio

5.77

Quick Ratio

3.68

Debt to Market Cap

0.00

Net Debt to EBITDA

-1.09

Interest Coverage Ratio

2.10

In the past 12 months, Xvivo Perfusion AB has paid 13.40M in taxes.

Income Tax

13.40M

Effective Tax Rate

0.35

Xvivo Perfusion AB EV to EBITDA ratio is 29.14, with an EV/FCF ratio of 32.57.

EV to Sales

6.51

EV to EBITDA

29.14

EV to Free Cash Flow

32.57

EV to Operating Cash Flow

23.21

Xvivo Perfusion AB has $313.24M in cash and marketable securities with $120.61M in debt, giving a net cash position of $192.63M billion.

Cash & Marketable Securities

$313.24M

Total Debt

$120.61M

Net Cash

$192.63M

Net Cash Per Share

$6.12

Tangible Book Value Per Share

$20.96

Gross margin is 64.09%, with operating margin of 12.83%, and net profit margin of 13.44%.

Gross Margin

64.09%

Operating Margin

12.83%

Pretax Margin

16.23%

Net Profit Margin

13.44%

EBITDA Margin

22.33%

EBIT Margin

12.84%

The average price target for Xvivo Perfusion AB is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

27.76%

EPS Growth Forecast

383.65%